Introduction
Histamine H1 receptor antagonists (antihistamines) are useful in the treatment of various allergic diseases such as allergic rhinitis, conjunctivitis, atopic dermatitis, urticaria, asthma and anaphylaxis (Mizushima, 2006) . Recently, there has been increasing interest in the metabolism and pharmacodynamic effects of classic antihistamines because of severe deleterious cytochrome P450 (P450)-based drug-drug interactions observed with second-generation antihistamines such as terfenadine (Paakkari, 2002; Monahan et al., 1990) . Diphenhydramine is a first-generation antihistamine synthesized in the 1940's (Loew et al., 1946) and has been widely used as an over-the-counter drug (Kay and Quig, 2001; Food and Drug Administration, 2002) . Since this antihistamine is available without prescription, it is possible that it is taken with various drugs so that an interaction may occur when the same P450 isozyme(s) is involved in the major metabolic processes of diphenhydramine and concomitant drug(s).
Diphenhydramine is extensively metabolized by demethylation to N-demethyl diphenhydramine followed by rapid demethylation to N,N-didemethyl diphenhydramine. N,N-Didemethyl diphenhydramine is further metabolized by oxidative deamination to diphenylmethoxyacetic acid. These metabolic pathways are thought to be major pathways in humans (Chang et al., 1974; Blyden et al., 1986) , although little is known about the enzymes involved in these metabolic pathways of diphenhydramine because of the limited requirements for pharmacokinetics/metabolism data prior to marketing classic antihistamines. However, the metabolism of classic antihistamines seems to be mediated by CYP2D6 because of the similar structural characteristics of many CYP2D6 substrates and inhibitors (de Groot et al., 1997; Koymans et al., 1992; Smith and Jones, 1992) . In fact, several classic antihistamines such as chlorpheniramine, mequitazine and promethazine have been shown to be metabolized by CYP2D6 (Yasuda et al., 2001; Nakamura et al., 1998; Nakamura et al., 1996) . In addition, previous studies revealed that diphenhydramine inhibited the metabolism of several CYP2D6 This article has not been copyedited and formatted. The final version may differ from this version. -5 -substrates in vivo and in vitro (Hamelin et al., 1998 (Hamelin et al., , 2000 He et al., 2002; Lessard et al., 2001 ).
These findings suggest that the metabolism of diphenhydramine is also mediated by CYP2D6.
However, Lessard et al. (2001) reported that the clearance of diphenhydramine to its N-demethylated metabolite (2-benzhydryloxy-N-methyl-ethanamine) is not different in extensive and poor metabolizer phenotypes of CYP2D6 and suggested that diphenhydramine is not extensively metabolized by this P450 isozyme. In addition, multiple P450 isozymes, CYP1A2, CYP2C18, CYP2C19, CYP2D6 and CYP2B6, have been reported to be involved in the N-demethylation of diphenhydramine at 20 µM (Hamelin et al., 2001, Sharma and Hamelin, 2003) . Nonetheless, it remains unclear whether these P450 isozymes also catalyze the N-demethylation of diphenhydramine at clinically relevant concentrations, which are 37 to 83 ng/ml (0.14 to 0.33 µM) in plasma after oral administration and 99 to 196 ng/ml (0.38 to 0.77 µM) in plasma after intravenous injection of 50 mg of diphenhydramine hydrochloride (Carruthers et al., 1978; Blyden et al., 1986) . Therefore, the aim of this study was to identify the P450 isozymes involved in N-demethylation of diphenhydramine using recombinant P450 isozymes and human liver microsomes at a clinically relevant concentration (0.5 µM) of diphenhydramine by a liquid chromatography-mass spectrometry (LC/MS) method developed in our laboratory.
Contributions of multiple P450 isozymes to human liver microsomal N-demethylation of diphenhydramine were also estimated by application of the relative activity factor (RAF) (Crespi et al., 1995) and were verified by the results of inhibition studies using P450 isozyme-specific inhibitors.
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Materials and methods

Chemicals and reagents
Diphenhydramine hydrochloride, quinidine sulfate, furafylline, sulfaphenazole and omeprazole were purchased from SIGMA (Milwaukee, WI). Orphenadrine hydrochloride was purchased from MP Biomedicals (Aurora, OH). SKF-525A was purchased from Toronto Research Chemicals (North York, Canada). Glucose 6-phosphate (G6P), glucose 6-phosphate dehydrogenase (G6PDH) and nicotinamide adenine dinucleotide phosphate (NADP + ) were purchased from Oriental Yeast Co. (Tokyo, Japan). 2-Benzhydryloxy-N-methyl-ethanamine (N-demethyl diphenhydramine) was synthesized by WAKO Pure Chemical Industries (Osaka, Japan). Human liver microsomes (HG3, 6, 23, 30, 42, 43, 56, 66, 70, 89, 93, 112 and pooled) and microsomes prepared from baculovirus-infected insect cells expressing CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A11 individually were obtained from BD Gentest (Woburn, MA). All recombinant P450s had been co-expressed with NADPH P450 oxidoreductase. Recombinant CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1 and CYP3A4 were also co-expressed with cytochrome b 5 . Microsomal protein expressing NADPH P450 oxidoreductase and cytochrome b 5 was used as a control. Other chemicals and reagents used in this study were research-grade purchased from WAKO.
Diphenhydramine N-demethylation assay
The basic incubation mixture contained recombinant P450 isozyme (5 pmol P450/ml) or human liver microsomes (0.1 mg/ml), 0.1 mM EDTA, 100 mM potassium phosphate buffer (pH 7.4), and 0.5 µM diphenhydramine in a final incubation volume of 250 µl. The reaction was initiated by the addition of an NADPH-generating system (0.5 mM NADP + , 2.0 mM G6P, 1 U/ml G6PDH and 4 mM MgCl 2 ). Incubation was performed for 20 min for recombinant P450 This article has not been copyedited and formatted. The final version may differ from this version. 
Solid phase extraction
Solid phase extraction was performed by the method of Miyaguchi et al. (2006) with slight modifications. The incubation mixture was applied to a mix-mode solid phase extraction cartridge (Oasis MCX cartridge, Waters, Milford, MA). The cartridge was conditioned with 1 ml each of acetonitrile and distilled water before use. After application of the reaction mixture, the cartridge was washed with 1 ml each of 0.1 M HCl and acetonitrile and then eluted with 1 ml of 5% ammonium hydroxide in acetonitrile. In this solid-phase extraction method, lipophilic basic compounds were selectively eluted. The eluate was dried under a gentle stream of nitrogen at 45˚C and reconstituted by 100 µl of distilled water/acetonitrile (50/50, v/v) . Ten µl of the reconstituted sample was applied to an LC/MS system. In this extraction procedure, the This article has not been copyedited and formatted. The final version may differ from this version. -8 -recovery rates of N-demethyl diphenhydramine were calculated by three or four independent analyses to be 100.0 ± 2.2% at 50 nM and 95.0 ± 2.2% at 5 µM. Coefficients of variation of this solid-phase extraction method were 2.2% at 50 nM and 2.3% at 5 µM.
LC/MS conditions
Determination of diphenhydramine and its N-demethylated metabolite was carried out using an LC/MS system. The LC system consisted of an Alliance 2695 separation module (Waters) and an XTerra MS C18 column (particle size of 3. 
Kinetics of diphenhydramine N-demethylation in pooled human liver microsomes
Correlation study
Correlation coefficients between diphenhydramine N-demethylation activity at 0.5 µM and other P450 isozyme-specific activities were calculated in human liver microsomes from 12 individual donors. Data of activities of phenacetin O-deethylation for CYP1A2, coumarin 7-hydroxylation for CYP2A6, (S)-mephenytoin N-demethylation for CYP2B6, paclitaxel 6α-hydroxylation for CYP2C8, diclofenac 4'-hydroxylation for CYP2C9, (S)-mephenytoin 4'-hydroxylation for CYP2C19, bufuralol 1'-hydroxylation for CYP2D6, chlorzoxazone 6-hydroxylation for CYP2E1, testosterone 6β-hydroxylation for CYP3A4 and lauric acid 12-hydroxylation for CYP4A were provided by BD Gentest.
Chemical inhibition study
The effects of P450 isozyme-specific inhibitors on diphenhydramine N-demethylation activity were investigated in human liver microsomes. Human liver microsomal protein (0.1 mg/ml) was incubated with 0.5 µM diphenhydramine in the presence of 1 µM quinidine (a selective CYP2D6 inhibitor) at 37˚C for 60 min. Correlation coefficients between the residual diphenhydramine N-demethylation activity in the presence of 1 µM quinidine and other P450 This article has not been copyedited and formatted. The final version may differ from this version. -10 -isozyme-specific activities were calculated in human liver microsomes from 12 individual donors. Inhibition studies with 10 µM furafylline for CYP1A2, 10 µM sulfaphenazole for CYP2C9 and 10 µM omeprazole for CYP2C19 in individual human liver microsomes HG30, HG66, HG89 and HG112 and in pooled human liver microsomes were also performed. These human liver microsomes from individual donors were selected because they showed characteristic activities of CYP2D6, CYP1A2, CYP2C9 and CYP2C19 and comparable activities of diphenhydramine N-demethylation. The concentrations of specific inhibitors were verified by inhibition of the specific activities of corresponding P450 isozymes in human liver microsomes (Bourrie et al., 1996; Kobayashi et al., 1999; Giraud et al., 2000) .
Kinetics of diphenhydramine N-demethylation in recombinant P450 isozymes
Kinetics of diphenhydramine N-demethylation in recombinant CYP1A2, CYP2C9, CYP2C19 and CYP2D6 were determined from formation rates of N-demethyl diphenhydramine at diphenhydramine concentrations ranging from 0.05 to 20 µM for CYP2D6 and from 0.5 to 500 µM for CYP1A2, CYP2C9 and CYP2C19. The kinetic parameters (Km, Vmax and Vmax/Km) were estimated by graphic analysis of the 1-component Michaelis-Menten model calculated by using DeltaGraph 4.5.
Contribution of each P450 isozyme to diphenhydramine N-demethylation in human liver microsomes
The percentage contribution of each P450 isozyme to diphenhydramine N-demethylation in human liver microsomes was estimated by application of the RAF (Crespi et al., 1995) . The 
Results
Diphenhydramine N-demethylation activity in recombinant P450 isozymes
Diphenhydramine N-demethylation activities at 0.5 µM in microsomes of baculovirus-infected insect cells expressing 14 individual P450 isozymes were determined (Fig.   2) . CYP2D6 showed the highest activity of diphenhydramine N-demethylation (0.69 pmol/min/pmol P450). The activity of recombinant CYP2C19 was 0.071 pmol/min/pmol P450, the second highest. Recombinant CYP1A2, CYP2B6 and CYP2C18 also showed diphenhydramine N-demethylation activities (0.043, 0.023 and 0.036 pmol/min/pmol P450, respectively), while CYP1A1, CYP2C9 and CYP3A4 showed detectable but low activity (0.010, 0.0082 and 0.0084 pmol/min/pmol P450, respectively).
Kinetics of diphenhydramine N-demethylation activity in pooled human liver microsomes
The Eadie-Hofstee plot for diphenhydramine N-demethylation activity in pooled human liver microsomes showed a biphasic pattern (data not shown). Vmax1 and Km1, kinetic parameters for the high-affinity component, were calculated to be 30.2 pmol/min/mg protein and 13.3 µM, respectively. Vmax2 and Km2, kinetic parameters for the low-affinity component, were calculated to be 551 pmol/min/mg protein and 401 µM, respectively. Each Parameter was calculated by the mean of three independent analyses.
Diphenhydramine N-demethylation activity in individual human liver microsomes
As shown in Fig. 3 , diphenhydramine N-demethylation activities at 0.5 µM varied 4.5 fold (0.87 to 3.89 pmol/min/mg protein) among 12 human liver microsomes tested.
Diphenhydramine N-demethylation activity in human liver microsomes was completely inhibited by SKF-525A (1 mM), a typical P450 inhibitor, which was incubated concomitantly with diphenhydramine, and was not detected in the absence of the NADPH generating system This article has not been copyedited and formatted. The final version may differ from this version. (Fig.   4A ). In HG89, having a low bufuralol 1'-hydroxylation activity and medium phenacetin O-deethylation, diclofenac 4'-hydroxylation and (S)-mephenytoin 4'-hydroxylation activity, diphenhydramine N-demethylation was inhibited by furafylline (56.0%), sulfaphenazole (25.8%) and omeprazole (37.0%) (Fig. 4C) . In HG112, having low bufuralol 1'-hydroxylation and phenacetin O-deethylation activity and high diclofenac 4'-hydroxylation and (S)-mephenytoin 4'-hydroxylation activity, diphenhydramine N-demethylation was inhibited by furafylline (11.8%), sulfaphenazole (34.8%) and omeprazole (54.1%) (Fig. 4D) . In pooled human liver microsomes, diphenhydramine N-demethylation was inhibited by furafylline (23.0%), sulfaphenazole (19.7%) and omeprazole (11.2%) (Fig. 4E) .
Kinetics of diphenhydramine N-demethylation in recombinant CYP1A2, CYP2C9, CYP2C19 and CYP2D6
Concentration-activity relationships for diphenhydramine N-demethylation activities of recombinant CYP1A2, CYP2C9, CYP2C19 and CYP2D6 were able to be fitted by a Michaelis-Menten equation. The kinetic parameters in recombinant CYP1A2, CYP2C9, CYP2C19 and CYP2D6 are listed in Table 2 . Vmax value of recombinant CYP2D6 was 2.38 ± 0.24 pmol/min/pmol P450. Recombinant CYP2D6 showed the lowest Km value (1.12 ± 0.21 µM). Vmax values of CYP1A2, CYP2C9 and CYP2C19 were 14.0 ± 2.3, 4.43 ± 0.28 and 11.0 ± 2.6 pmol/min/pmol P450, respectively. Km values of CYP1A2, CYP2C9 and CYP2C19 were 295 ± 46, 134 ± 32 and 55.7 ± 6.5 µM, respectively.
Contributions of CYP1A2, CYP2C9, CYP2C19 and CYP2D6 to diphenhydramine N-demethylation in human liver microsomes
This article has not been copyedited and formatted. The final version may differ from this version. Fig. 5A . In HG66, which showed a high level of bufuralol 1'-hydroxylation activity, the contribution of CYP2D6 to diphenhydramine N-demethylation was estimated to be up to 80%, whereas the contributions of CYP1A2, CYP2C9 and CYP2C19 were low. In HG30, HG89 and HG112, which showed no detectable or low levels of bufuralol 1'-hydroxylation activity, the contribution of CYP2D6 to diphenhydramine N-demethylation was estimated to be negligible or low (0 to 12.1%). On the other hand, contributions of CYP1A2, CYP2C9 and CYP2C19 in these microsomes were estimated to be relatively high (around 30%) for each isozyme except for CYP1A2 in HG112 (4.2%), which showed a low phenacetin O-deethylation activity. In pooled human liver microsomes, the contribution of CYP2D6 was estimated to be half of the total activity of diphenhydramine N-demethylation.
Contributions of CYP1A2, CYP2C9, CYP2C19 and CYP2D6 to diphenhydramine N-demethylation estimated by the application of RAFs and by the results of inhibition studies were compared in Fig. 5A and 5B. Contributions of these P450 isozymes to diphenhydramine N-demethylation estimated by the application of RAFs (Fig. 5A) were in good agreement with those estimated by inhibition studies using P450 isozyme-specific inhibitors in four individual samples and one pooled sample of human liver microsomes (Fig. 5B ).
Discussion
In the present study, the highest level of activity of diphenhydramine N-demethylation was found in recombinant CYP2D6 at a clinically relevant concentration (0.5 µM) by an LC/MS method developed in our laboratory (Fig. 2) . A significant correlation was also found between diphenhydramine N-demethylation activity and bufuralol 1'-hydroxylation activity (r = 0.672, p < 0.05) in human liver microsomes from 12 individual donors (Table 1) . Moreover, diphenhydramine N-demethylation was strongly inhibited by quinidine in human liver microsomes having a high level of CYP2D6 activity (HG66, Fig. 4B) . Furthermore, the Km value for diphenhydramine N-demethylation of recombinant CYP2D6 is the lowest (1.12 ± 0.21 µM) among P450 isozymes tested (Table 2 ). These results indicate that N-demethylation of diphenhydramine is mainly catalyzed by CYP2D6 as a high-affinity P450 isozyme in vitro.
In a previous case report, the half-life of diphenhydramine was 2-fold greater than the usual value in an elderly woman who had a prolonged half-life of imipramine (Glassman et al., 1985) , which is mainly metabolized by CYP2D6 (Koyama et al., 1997) , suggesting that diphenhydramine is a substrate of CYP2D6 in vivo. In addition, diphenhydramine is known to inhibit the metabolism of several other CYP2D6 substrates in vitro and in vivo (Hamelin et al., 1998; He et al., 2002; Hamelin et al., 2000; Lessard et al., 2001) . These findings coupled with the results of the present study suggest that diphenhydramine is not only a potent inhibitor of CYP2D6 but also a high-affinity substrate of CYP2D6 in vitro and in vivo.
Since an Eadie-Hofstee plot in pooled human liver microsomes showed a biphasic pattern, multiple P450 isozymes are thought to be involved in N-demethylation of diphenhydramine in addition to CYP2D6. In the present study, we obtained several results supporting the involvement of CYP1A2, CYP2C9 and CYP2C19 in N-demethylation of diphenhydramine as low-affinity components. In previous studies Sharma and Hamelin 2003) , N-demethylation of diphenhydramine was reported to be mediated by multiple P450 isozymes, This -17 -CYP1A2, CYP2C18, CYP2C19, CYP2D6 and CYP2B6, at 20 µM. This finding is consistent with the results of the present study showing that CYP1A2 and CYP2C19 are involved in diphenhydramine N-demethylation as low-affinity components, whereas it is inconsistent with the finding in the present study that CYP2C9 is involved as one of the low-affinity enzymes in diphenhydramine N-demethylation. However, the results of the present study showed that diclofenac 4'-hydroxylation was significantly correlated with diphenhydramine N-demethylation activity (r = 0.822, p < 0.01) in human liver microsomes from 12 individual donors when CYP2D6 activity was inhibited by quinidine (Table 1) . Furthermore, an inhibitory effect of sulfaphenazole on N-demethylation of diphenhydramine was seen in human liver microsomes having low levels of or no detectable activity of CYP2D6 (Fig. 4) and was in good agreement with the contribution of CYP2C9 estimated by application of the RAF (Fig. 5) .
Therefore, diphenhydramine N-demethylation seems to be mediated by CYP2C9 in addition to CYP1A2 and CYP2C19 as low-affinity components in human liver microsomes. In the present study, although a significant correlation was also found between lauric acid 12-hydroxylation and diphenhydramine N-demethylation activity (Table 1) , involvement of CYP4A was not examined because a correlation was not found when CYP2D6 was inhibited by quinidine (Table 1) and diphenhydramine N-demethylation activity was not detectable in recombinant CYP4A11 (Fig. 2) . In addition, involvement of CYP2C18 and CYP2B6 was not examined in the present study because the results of inhibition studies using P450 isozyme-specific inhibitors in individual and pooled human liver microsomes showed that low-affinity components involved in N-demethylation of diphenhydramine are almost completely explained by CYP1A2, CYP2C9 and CYP2C19 (Fig. 4) .
The main adverse effects of classic antihistamines are effects on the central nervous system such as sedation, impairment of cognitive function and psychomotor performance (Hindmarch and Shamsi, 1999; Welch and Meltzer, 2002) . The sedative effect of This article has not been copyedited and formatted. The final version may differ from this version. -18 -diphenhydramine has been reported to be correlated with its plasma concentration (Carruthers et al., 1978) . Therefore, when the major metabolic process of diphenhydramine and a concomitant drug(s) is mediated by the same P450 isozyme(s), a sedative effect may be induced by an increase in the plasma concentration of diphenhydramine. The results of the present study indicate that diphenhydramine is mainly metabolized by CYP2D6, which is known to catalyze the oxidative metabolism of various clinically important drugs (Zanger et al., 2004) . In addition, since diphenhydramine is available without prescription (Food and Drug Administrations, 2002) , it is possible that it is taken with various drugs. Therefore, it should be emphasized that the plasma concentration of diphenhydramine may be increased and a sedative effect may be induced by co-administration of CYP2D6 substrates/inhibitors. Besides, in the case of poor metabolizer phenotypes of CYP2D6, drug-drug interaction may occur between diphenhydramine and substrates/inhibitors/inducers of CYP1A2, CYP2C9 and CYP2C19, because N-demethylation of diphenhydramine seems to be mediated by these P450 isozymes as low-affinity components.
In the present study, diphenhydramine N-demethylation activities at 0.5 µM varied 4.5 fold (0.87 to 3.89 pmol/min/mg protein) among human liver microsomes tested (Fig. 5) . In addition, the results of the present study indicate that diphenhydramine N-demethylation is mainly catalyzed by CYP2D6. Therefore, the plasma concentration of diphenhydramine is thought to be influenced by the metabolic activity of CYP2D6, which varies extensively among individuals who can be categorized on the basis of their CYP2D6 activity as ultrarapid, extensive, intermediate, and poor metabolizers, which are reflected by CYP2D6 genetic polymorphism (Zanger et al., 2004) . However, a previous study showed that the clearance of diphenhydramine to its N-demethylated metabolite was not different in extensive and poor metabolizer phenotypes of CYP2D6 (Lessard et al., 2001) -19 -differences in plasma concentration of diphenhydramine could be caused by large differences in metabolic activities of CYP1A2, CYP2C9 and CYP2C19 (Chiba, 1998; Kirchheiner and Brockmoller, 2005; Furuta et al., 2005) . Furthermore, CYP1A2 is known to be a P450 isozyme inducible by environmental factors such as polycyclic aromatic hydrocarbons (Pelkonen et al., 1998; Sherson et al., 1992) . Therefore, the effects of genetic polymorphisms of CYP2D6 on the disposition of diphenhydramine may be masked by the interindividual differences in the metabolic capacity of these P450 isozymes. Further studies are needed to clarify the involvement of CYP2D6 in the metabolism of diphenhydramine N-demethylation as a major enzyme in vivo. Such study is now underway in our laboratory.
In conclusion, N-demethylation of diphenhydramine is mainly catalyzed by CYP2D6 as a high-affinity P450 isozyme at a clinically relevant concentration. Therefore, it seems that diphenhydramine is not only a potent inhibitor of CYP2D6 but also a high-affinity substrate of CYP2D6. It should be noted that the sedative effect of diphenhydramine might be caused by an increase in the plasma concentration of diphenhydramine by concomitant use of CYP2D6 substrates/inhibitors. In addition, CYP1A2, CYP2C9 and CYP2C19 are involved in the metabolism of diphenhydramine as low-affinity P450 isozymes. Therefore, it should also be noted that diphenhydramine might interact with substrates/inhibitors/inducers of these P450 -27 -32. 1, 27.4 and 4.6%, respectively, in HG89; 4.2, 35.8, 47.9 and 12.1%, respectively, in HG112; and 14.2, 27.5, 9 .9 and 48.4%, respectively, in pooled human liver microsomes.
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